Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 9/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219564 | 0.88 | OPRM1 (0.54) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6483596 | 0.84 | OPRM1 (0.59) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7095606 | 0.80 | OPRM1 (0.58) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7091407 | 0.80 | OPRM1 (0.58) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7093813 | 0.80 | OPRM1 (0.58) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7091540 | 0.80 | OPRL1 (0.59) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6476773 | 0.79 | OPRM1 (0.58) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL6484497 | 0.78 | OPRM1 (0.61) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7095902 | 0.78 | OPRM1 (0.71) | OPRL1OPRD1OPRM1OPRK1KCNH2 | |
| SCHEMBL7091980 | 0.78 | OPRM1 (0.57) | OPRL1OPRD1OPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122257-B1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6861425-B2 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049212-A1 | Benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OGFRL1 | OPRL1 1/4885OPRD1 5/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.